PBM
Pharmacy Benefit Manager—a middleman that negotiates drug discounts and rebates from drug companies and helps health plans decide what to charge patients and which drugs to cover.
As defined in Robin Feldman on Drugs, Money, and Secret Handshakes
Where it comes up · 11
- Robin Feldman on Drugs, Money, and Secret Handshakes12 claims
- UnitedHealth Group: Beyond The Premium4 claims
- Mark Cuban4 claims
- RTW: Investing Across Healthcare2 claims
- Evolution designed us to die fast; we can change that — Jacob Kimmel2 claims
- Kareem Zaki - Small Ideas Attract Competition - [Invest Like the Best, EP.392]2 claims
- Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]2 claims
- Marty Makary on the Price We Pay1 claim
and 3 more
Most important claims · 10 of 32Search all claims for “PBM” →
- Most businesses are overpaying on health and pharmacy plans because the broker industry that sells them takes commissions for life (regulated at 4% in New York) plus back-end kickbacks from insurers to retain business, an industry as corrupted as the subprime mortgage broker industry, placing employers in plans they shouldn't be in.Marty Makary on the Price We Pay
- Healthcare is local with two or three insurers and one to three health systems per market, three PBMs control 80% of the market, and IT providers are concentrated, so the absence of competition removes urgency to change and fails to reward good behavior.Kareem Zaki - Small Ideas Attract Competition - [Invest Like the Best, EP.392]
- US healthcare consumes over 25% of the federal budget, growing faster than inflation, costs employers more than R&D, and is the leading cause of consumer bankruptcy, yet quality is not better than the best countries in the world despite far higher spending.Kareem Zaki - Small Ideas Attract Competition - [Invest Like the Best, EP.392]
- Self-insured companies blindly offload healthcare expertise to benefits consultants who steer them to the highest-commission vendors; Cuban found he paid $30/employee/month for such consultants and that buying generics through Cost Plus would have cost the Mavericks $19,000 versus $169,000 via a big-three PBM, so companies should internalize this expertise because employee wellness directly affects performance.Mark Cuban
- Long-durability medicines whose benefits accrue years later face a reimbursement problem because Americans change insurers every 3-4 years, so no insurer is incentivized to cover a benefit realized in the out-years; a pay-for-performance model—paying a fraction of the cost each year contingent on demonstrated ongoing benefit—aligns incentives, treating the therapeutic's cost-lowering effect like a pre-existing condition that follows the patient between payers.Evolution designed us to die fast; we can change that — Jacob Kimmel
- The big three PBMs (CVS Caremark, Express Scripts, Optum Rx) put profits over everything by exploiting an opaque industry: contracts forbid disclosure, so they can tell different client companies different 'great prices' while neither knows the true cost or markup, and they even underpay contracted rebates because there's no way for clients to verify.Mark Cuban
- After Obamacare capped insurers' profits, insurers consolidated hospitals, doctors' practices, and PBMs to keep growing, leaving drug companies as the only major part of the ecosystem they could not buy, which turned the system into an us-versus-them fight aimed at drugmakers.RTW: Investing Across Healthcare
- US out-of-pocket drug costs at the pharmacy counter are too high, in part because insurers bent the cost curve by shifting costs onto drugs, which are easier to skip than hospital care, so public anger has landed on drugmakers rather than insurers.RTW: Investing Across Healthcare
- When pharma sold GLP-1s direct to consumers, the list-to-net gap was eliminated by removing PBMs and insurers, and prices fell from about $1,300 list to about $149 cash, while drugmakers still earned more gross profit.Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
- The big three PBMs reimburse community pharmacies less than their net cost for brand drugs (e.g. reimbursing $500 or less on a drug with $550 net investment), especially under Medicare Part D and Advantage, making the government complicit in driving tens of thousands of independent pharmacies out of business — which in turn motivates big-brand manufacturers to work with Cost Plus to support independents and break the cartel's vertical integration.Mark Cuban